PNEUMOCYSITIS CARINII INFECTION THERAPIES--PRECLIN EVAL

本合同的总体目标是促进发现和 具有治疗和预防潜力的治疗方法的发展 在艾滋病患者中发现卡氏肺孢子虫肺炎。 本合同的预期履约情况是定量评估 治疗卡氏肺孢子虫肺炎的有效药物 在标准化的、经过验证的老鼠模型测试系统中，包括 在初级小鼠模型中对联合治疗的评估， 在初级小鼠模型中预防方案中的药物评估， 以及在大鼠模型中对治疗方法的评估。治疗性的 代理商将在标准化的、可重复的 和经过验证的体外(培养)测试系统 有机体。

The overall objective of this contract is to facilitate discovery and development of therapies with potential for treatment and prophylaxis of Pneumocystis carinii pneumonia in people with AIDS. The expected performance of this contract is to quantitatively evaluate therapeutic agents for efficacy against Pneumocystis carinii pneumonia in a standardized, validated mouse model test system, to include evaluation of therapies in combination in the primary mouse model, drug evaluations in prophylaxis protocols in the primary mouse model, and evaluation of treatment therapies in a rat model. Therapeutic agents will be evaluated for activity in a standardized, reproducible and validated in vitro (culture) test system which employs intact organisms.